Clinical trials: Chimeric Antigen Receptor T-cell Therapy
B-All, Acute Lymphoblastic Leukemia
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Background: B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene mutation that makes the disease hard to treat.
- Trial name
- NCT07572136
- Testing
- TSLPR-CART, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
CAR-T Therapy Complications
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of oncohematological pathologies…
- Trial name
- CAR_21_01 (NCT04892433)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Plasma Cell Neoplasms
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
- Trial name
- NCT07586709
- Testing
- In vivo BCMA/GPRC5D Tandem Dual CAR-T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liping Dou
Relapse Multiple Myeloma
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
- Trial name
- NCT07359014
- Testing
- Dual CD19/BCMA CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
The purpose of the CARMic study is to investigate whether a restrictive, microbiome-sparing antibiotic strategy can better preserve the gut microbiota in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy…
- Conditions
- Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota
- Trial name
- CARMic (NCT07842198)
- Testing
- ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Follicular Lymphoma, B-Cell Lymphoma
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and…
- Conditions
- Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT05934838
- Testing
- Tazemetostat Pill
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Hematologic Malignancies
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
The overall purpose of this randomized control trial (RCT) is to determine the clinical effect of a multilevel, RPM-enhanced intervention during and after completion of outpatient CAR-T therapy in 190 patients and their family…
- Trial name
- NCT07186192
- Testing
- Educational Intervention, Health Telemonitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed…
- Trial name
- CORAL (NCT06788964)
- Testing
- Loncastuximab Tesirine, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Utah
B Cell Lymphoma, Multiple Myeloma
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety and efficacy of CD19 and B-cell maturation antigen (BCMA) targeted allogenic CAR-T cells (RN1101) in patients with relapsed/refractory B-cell or plasma…
- Trial name
- NCT06976437
- Testing
- RN1101 injection
- Where
- China
- Volunteers
- 21 people
- Sponsor
- YANRU WANG
Multiple Myeloma
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-3 (NCT06235229)
- Testing
- GC012F
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Refractory Glioblastoma, Recurrent Glioblastoma
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
This study is an investigator-initiated, open-label Phase I clinical trial designed to evaluate the safety and efficacy of EPC-003 fully human anti-B7H3/IL13Ra2 armored Chimeric Antigen Receptor T-Cell Therapy (CAR-T) cell…
- Trial name
- NCT07193628
- Testing
- EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2), EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Safety and Efficacy of TCR-like CAR-T
Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer
The goal of this clinical trial is to test TCR-like CAR-T in the Treatment of MSLN positive Ovarian Cancer. The main question it aims to answer are: the safety and efficacy of TCR-like CAR-T in the Treatment of MSLN positive…
- Trial name
- NCT05963100
- Testing
- TCR-like CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhongda Hospital
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy…
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT05633615
- Testing
- Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography
- Where
- 95 sites in United States
- Volunteers
- 396 people
- Sponsor
- SWOG Cancer Research Network
Sarcoma, Childhood Osteosarcoma
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.
- Conditions
- Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT07222735
- Testing
- Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Hepatocellular Carcinoma
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
A phase I clinical study of 4th generation chimeric antigen receptor T Cells targeting glypican-3 ( CAR-GPC3 T Cells) in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT06461624
- Testing
- anti-GPC3 CAR-T
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Refractory Multiple Myeloma
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
- Trial name
- NCT07377435
- Testing
- DC/MM Fusion Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- David Avigan
Relapsed/Refractory Multiple Myeloma
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine…
- Trial name
- NCT05000450
- Testing
- ALLO-605, ALLO-647, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Allogene Therapeutics
Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP)
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA(BZE2204) in…
- Conditions
- Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE)
- Trial name
- NCT07174843
- Testing
- CD19/CD22/BCMA CAR-T cells(BZE2204)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative…
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL
- Trial name
- NCT04881240
- Testing
- CD19-CAR(Mem) T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.